Suchen
Immunoprecise Antibodies Ltd
IPAZur Watchlist hinzufügen
2.070USD
0.0000.00%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
95.54MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Immunoprecise Antibodies Ltd Unternehmen
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
Immunoprecise Antibodies Ltd Informationen
BörsenkürzelIPA
Name des UnternehmensImmunoprecise Antibodies Ltd
IPO-datumJan 30, 1987
CEODr. Jennifer Lynne Bath, Ph.D.
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeJan 30
AddresseIndustrious 823 Congress Ave Suite 300
StadtAUSTIN
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl78701
Telefon16048060626
Websitehttps://www.ipatherapeutics.com/
BörsenkürzelIPA
IPO-datumJan 30, 1987
CEODr. Jennifer Lynne Bath, Ph.D.
Führungskräfte von Immunoprecise Antibodies Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jennifer Lynne Bath, Ph.D.
Dr. Jennifer Lynne Bath, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
498.12K
--
Dr. Kamil Isaev
Dr. Kamil Isaev
Independent Director
Independent Director
3.19K
--
Mr. Dirk Witters
Mr. Dirk Witters
Independent Director
Independent Director
1.95K
--
Ms. Kari Graber
Ms. Kari Graber
Vice President - Commercial Services
Vice President - Commercial Services
700.00
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Director
Director
--
--
Mr. Joseph Scheffler
Mr. Joseph Scheffler
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Shuji Sato
Dr. Shuji Sato
Vice President - Innovative Solutions
Vice President - Innovative Solutions
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jennifer Lynne Bath, Ph.D.
Dr. Jennifer Lynne Bath, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
498.12K
--
Dr. Kamil Isaev
Dr. Kamil Isaev
Independent Director
Independent Director
3.19K
--
Mr. Dirk Witters
Mr. Dirk Witters
Independent Director
Independent Director
1.95K
--
Ms. Kari Graber
Ms. Kari Graber
Vice President - Commercial Services
Vice President - Commercial Services
700.00
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Director
Director
--
--
Mr. Joseph Scheffler
Mr. Joseph Scheffler
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Immunoprecise Antibodies Ltd?
Die fünf größten Anteilseigner von Immunoprecise Antibodies Ltd sind: Dr. Jennifer Lynne Bath, Ph.D.
Wie viele Institutionen halten Anteile an Immunoprecise Antibodies Ltd (IPA)?
Mit Stand vom 2026Q1 halten 47 Institutionen Anteile an Immunoprecise Antibodies Ltd, mit einem Gesamtmarktwert von etwa 4.54M, was 9.73% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 212280.00 gestiegen.
Was ist die größte Einnahmequelle von Immunoprecise Antibodies Ltd?
Am 2026Q1 erzielte das Geschäft mit Project revenue für Immunoprecise Antibodies Ltd den höchsten Umsatz in Höhe von 4.11M, was 98.85% des Gesamtumsatzes entspricht.